Leishmania vaccines

A method of eliciting an immune response against Leishmania donovani infection in a mammal, the method comprising administering to the mammal a DNA vaccine, the DNA vaccine comprising at least one vector, the at least one vector encoding at least A2 gene from Leishmania donovani, whereby expression of the gene in one or more cells of the mammal elicits at least one of a humoral immune response and a cell-mediated immune response against any Leishmania species.

A method of optimising a DNA vaccine comprising co-administering the DNA vaccine with a vector encoding a selected gene, the selected gene being capable of mediating degradation of cellular protein p53.

A DNA vaccine against Leishmania infection comprising a plasmid vector encoding A2 gene from Leishmania donovani in a pharmaceutically acceptable carrier.

A DNA vaccine comprising a plasmid vector encoding A2 gene from Leishmania donovani and a biological adjuvant in pharmaceutically acceptable carrier.

A DNA vaccine comprising a plasmid vector encoding A2 gene from Leishmania donovani and the Human papillomavirus E6 gene in a pharmaceutically acceptable carrier.

A plasmid vector comprising a DNA sequence encoding A2 gene from Leishmania donovani.

A plasmid vector comprising a DNA sequence encoding A2 gene from Leishmania donovani and Human papillomavirus E6 gene.

The use of a plasmid vector in a vaccine for eliciting an immune response against Leishmania donovani infection in a mammal, wherein said plasmid comprising a DNA sequence encoding A2 gene from Leishmania donovani.

The use of a plasmid vector in a vaccine for eliciting an immune response against Leishmania donovani infection in a mammal, wherein said plasmid comprising a DNA sequence encoding A2 gene from Leishmania donovani and Human papillomavirus E6 gene.

A method of-eliciting an immune response against Leishmania infection in a mammal, the method comprising administering to the mammal an initial dose of recombinant A2 protein and a pharmaceutically suitable adjuvant.

The use of recombinant Leishmania donovani A2 protein in inhibiting and/or preventing Leishmania infection in a mammal.

The use of Human papillomavirus E6 gene to mediate p53 degradation for increasing antibody production in a host.

The use of a vector for increasing antibody production in a host wherein said vector encoding a selected gene, the selected gene being capable of mediating degradation of cellular protein p53.

The use of a vector encoding Human papillomavirus E6 gene for mediating p53 degradation and increasing antibody production in a host.

A method of producing antibodies to a protein in a host comprising the steps of administering to the host a vector encoding a selected gene, the selected gene being capable of mediating degradation of cellular protein p53.

A method of producing antibodies to a protein in a host comprising the steps of administering to the host a vector encoding a mediator, the mediator being capable of mediating degradation of cellular protein p53.

The use of a mediator to mediate p53 degradation in a host for increasing antibody production in the host.